Eterna Therapeutics
ERNA
6 hedge funds and large institutions have $2.66M invested in Eterna Therapeutics in 2016 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
13% less capital invested
Capital invested by funds: $3.04M → $2.66M (-$380K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$11K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
ERNA Hedge Fund Activity: Q1 2016 in Review
6 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2016, worth a combined $2.66M — down 13% from $3.04M a quarter earlier.
Fund positioning in ERNA was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Virtu KCG Holdings, cutting an estimated $11K.
- 6 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $2.66M of Eterna Therapeutics stock for Q1 2016, down 13% quarter-over-quarter.
- 0 funds opened new Eterna Therapeutics positions in Q1 2016 and 0 closed out.
- The largest Eterna Therapeutics seller in Q1 2016 was Virtu KCG Holdings, an estimated $11K sold.
Based on aggregated 13F filings for Q1 2016.